Search

everythinglearnresearchcommunity

for

Search:↓

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

Regret over not starting hair loss treatments like finasteride and minoxidil earlier, leading to significant hair loss. Users discuss coping strategies, including buzzing hair, staying on medications, and considering future treatments.

Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.

The user noticed hair thinning since age 15, initially attributed to a Vitamin D deficiency. They are currently using Rogaine and considering Propecia but are hesitant about a scalp biopsy; they seek financially practical treatments for male-pattern baldness.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

A 22-year-old had a 3,500 graft hair transplant to restore his original hairline and improve density, while using dutasteride and oral minoxidil to manage hair loss. He believes being proactive with medication prevented further loss and allowed for a successful transplant.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

The post and conversation are about hair transplant tips and experiences. The user emphasizes thorough planning, essential packing, and post-surgery care, and regrets not using finasteride earlier.

A user is concerned about receding hairlines and considers using finasteride and minoxidil but is hesitant due to potential side effects. Others advise starting treatment early to prevent further hair loss, emphasizing that finasteride is generally safe and effective for prevention.

An 18-year-old started taking finasteride for early-stage hair loss, prescribed by a dermatologist who advised against waiting due to potential follicle loss. The conversation includes differing opinions on starting finasteride early, with some users sharing personal experiences and concerns about potential side effects.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

A 30-year-old with a family history of receding hairlines is considering starting finasteride due to gradual hairline recession. They are seeking advice on whether to begin treatment or if they are worrying unnecessarily.

Stem cell therapy shows promise in treating hair loss by mimicking DHT-resistant cells from the back of the head. Traditional treatments like finasteride are also discussed, but stem cells could potentially offer a more permanent solution.

A user experienced continuous hair shedding for 13 months after starting finasteride, suspecting it might cause chronic telogen effluvium, and considered switching to dutasteride or stopping medication. Other users suggested that finasteride doesn't cause hair loss, recommending dutasteride for more aggressive hair loss, while some advised against stopping medication.

A user with kidney disease and high blood pressure experienced hair thinning, especially around the vertex. They are currently using finasteride and oral minoxidil but are considering whether to resume blood pressure medication despite managing symptoms with diet and exercise.

PP405 is being discussed as a potential treatment for hair loss, with uncertainty about its effectiveness compared to existing treatments like finasteride, dutasteride, and minoxidil. There is cautious optimism, but its impact on hair transplants remains unclear.

A 19-year-old is experiencing early hair loss, possibly due to oily skin, stress, poor diet, and lack of sleep. They have tried ketoconazole shampoo without success and plan to visit a dermatologist for further advice.

The user has been using topical minoxidil and finasteride for hair loss, with some regrowth at the temples but continued hairline thinning. The dermatologist suggested possible telogen effluvium due to stress and deficiencies, prescribed oral minoxidil, and may consider dutasteride if the condition doesn't improve by January 2026.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

A 20-year-old female with PCOS is experiencing hair loss and excessive facial hair. She is using ketoconazole and caffeine shampoos, microneedling, and considering anti-androgens like finasteride, but is cautious about minoxidil due to facial hair concerns.

Early hair loss causes emotional distress, and common coping strategies like fitness and fashion are inadequate. Treatments like finasteride, minoxidil, dutasteride, hair systems, and scalp micropigmentation were tried but were unsatisfactory.

Celonius discusses hair loss and plans for a FUE Hair Transplant, but worries about how it will look when shaved in the future. Derhab21 suggests going for the transplant and mentions potential future treatments like Breezula and stem cell injections.

The conversation discusses severe hair loss, possibly due to telogen effluvium or male pattern baldness, lasting over three years. Suggested treatments include minoxidil, finasteride, and dermarolling, with a recommendation to consult a dermatologist.

The use of tropoelastin injections and verteporfin for hair transplant recipients to help regrow donor area hairs, as well as research done on tropoelastin injections restoring elastin in scarred heart tissue and skin. There are discussions about why it is taking so long to get cosmetic mass produced tropoelastin injectables on the market.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

The conversation discusses the potential of verteporfin in treating hair loss, with some users reporting positive results and speculating that it could lead to a cure for baldness. Others are skeptical, and there's a debate on the effectiveness of verteporfin for regrowing hair and reducing transplant scars.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.